MMM
MMM
Hold 2026-03-29
Model
DCF
Price at Report
$143.04
Base IV
$150.63
Bear IV
$78.19
Bull IV
$224.52
Entry Zone: 82-139 · Sell Above: 191
Bore Family Office
Valuation Report — 3M Company (MMM) • March 29, 2026
Unlevered DCF (FCFF @ WACC) • Discount Rate: 7.80% • Current Price: $143.04
Prepared by Lurch • Bore Family Office • Data: Finnhub, StockAnalysis.com, S&P Global Market Intelligence
🏢 Business Overview
3M Company (NYSE: MMM) is a global diversified industrial and consumer technology manufacturer founded in 1902, with operations in over 70 countries and ~85,000 employees. Following the 2024 spin-off of its Health Care segment (now Solventum) and the 2023 settlement of Combat Arms Earplugs litigation ($6.0B), 3M is a leaner three-segment company focused on Safety & Industrial, Transportation & Electronics, and Consumer products.
3M holds defensible competitive positions through its material science expertise, manufacturing scale, and an estimated 60,000+ patents — though it continues to navigate PFAS-related liabilities and a post-restructuring earnings recovery cycle.
| Business Segment | Revenue | % of Total | YoY Growth | Margin | Notes |
|---|---|---|---|---|---|
| Safety & Industrial | $11,380M | 46% | +3.9% | — | Abrasives, adhesives, personal safety, electrical; accelerating from +2.5% H1 to +3.9% H2 2025 |
| Transportation & Electronics | $8,270M | 33% | -1.3% | — | Automotive films, display materials, electronics interconnects; mild organic decline in 2025 |
| Consumer | $4,920M | 20% | -0.2% | — | Post-it, Scotch, Command, Filtrete; largely flat amid retailer inventory normalization |
| Corporate / Eliminations | $372M | 2% | +0.0% | — | Intersegment eliminations and corporate items |
| Blended Growth Rate | — | 100% | +1.3% | — | Weighted avg across segments |
🔍 Quality Scorecard
| Metric | Value | Assessment |
|---|---|---|
| ROIC | 12.0% | ≥12% strong |
| FCF Margin | 5.6% | 5–10% adequate |
| Debt / EBITDA | 2.1x | 2–4x moderate |
| Revenue Trend | Mixed | 3-year directional trend |
| FCF Margin Trend | Expanding | Directional margin trajectory |
| Analyst Revisions | Upward revisions | Last 90 days consensus direction |
✅ Quality profile supports the valuation
📊 Financial Snapshot
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue ($M) | $35,355 | $26,161 | $24,610 | $24,575 | $24,948 |
| Rev YoY Growth | — | -26.0% | -5.9% | -0.1% | +1.5% |
| Gross Margin | 46.8% | 39.4% | 39.1% | 41.2% | 39.9% |
| EBITDA ($M) | $9,284 | $6,200 | $-8,702 | $6,185 | $5,937 |
| EBITDA Margin | 26.3% | 23.7% | -35.4% | 25.2% | 23.8% |
| Operating Income ($M) | $7,369 | $4,369 | $-10,689 | $4,822 | $4,629 |
| Operating Margin | 20.8% | 16.7% | -43.4% | 19.6% | 18.6% |
| Net Income ($M) | $5,921 | $5,777 | $-6,995 | $4,173 | $3,250 |
| Net Margin | 16.7% | 22.1% | -28.4% | 17.0% | 13.0% |
| EPS (diluted) | $10.12 | $10.18 | $-12.63 | $7.55 | $6.00 |
| Free Cash Flow ($M) | $5,851 | $3,842 | $5,065 | $638 | $1,396 |
| Annual DPS | $5.920 | $5.960 | $6.000 | $3.610 | $2.920 |
| Total Debt ($M) | $18,217 | $16,780 | $16,691 | $13,044 | $12,602 |
📈 DCF Scenarios
$78
🔴 Bear
$151
📊 Base
$225
🚀 Bull
$143.04
Current Price
$174
Analyst Avg PT
| Scenario | Stage 1 (Yrs 1–5) | Stage 2 (Yrs 6–10) | Terminal g | WACC | Intrinsic Value | vs Price |
|---|---|---|---|---|---|---|
| 🔴 Bear | 1.0% | 1.0% | 2.0% | 7.80% | $78 | ▼45.3% |
| 📊 Base | 6.0% | 4.0% | 2.5% | 7.80% | $151 | ▲5.3% |
| 🚀 Bull | 9.0% | 6.0% | 3.0% | 7.80% | $225 | ▲57.0% |
📋 Full 10-Year Projection Tables
Bear Scenario
Stage 1: 1.0% | Stage 2: 1.0% | Terminal: 2.0%
| Period | Stage | FCFF | PV of FCFF | Cumulative EV |
|---|---|---|---|---|
| Year 1 ✦ | Stage 1 | $2.80B | $2.60B | $2.60B |
| Year 2 ✦ | Stage 1 | $2.90B | $2.50B | $5.09B |
| Year 3 ✦ | Stage 1 | $3.00B | $2.39B | $7.49B |
| Year 4 ✦ | Stage 1 | $3.10B | $2.30B | $9.78B |
| Year 5 ✦ | Stage 1 | $3.20B | $2.20B | $11.98B |
| Year 6 | Stage 2 | $3.23B | $2.06B | $14.04B |
| Year 7 | Stage 2 | $3.26B | $1.93B | $15.97B |
| Year 8 | Stage 2 | $3.30B | $1.81B | $17.78B |
| Year 9 | Stage 2 | $3.33B | $1.69B | $19.47B |
| Year 10 | Stage 2 | $3.36B | $1.59B | $21.06B |
| Terminal | — | TV=$59.1B | PV(TV)=$27.9B (57% of EV) | EV=$49.0B |
| Intrinsic Value | — | — | EV $49.0B − Net Debt → Equity / Shares | $78 |
How the price per share is derived: Each year's projected free cash flow is discounted back at WACC (7.80%) to get its present value. After Year 10, FCF grows at the terminal rate (2.0%) in perpetuity — the Gordon Growth formula gives a terminal value of FCF11 / (WACC − gT) = $59.1B. That terminal value is discounted back 10 years to today's dollars (PV of TV = $27.9B). Enterprise Value = PV of FCFs ($21.1B) + PV of TV ($27.9B) = $49.0B. Subtracting net debt gives equity value of $42.3B, divided by shares outstanding = $78 per share.
Base Scenario
Stage 1: 6.0% | Stage 2: 4.0% | Terminal: 2.5%
| Period | Stage | FCFF | PV of FCFF | Cumulative EV |
|---|---|---|---|---|
| Year 1 ✦ | Stage 1 | $3.60B | $3.34B | $3.34B |
| Year 2 ✦ | Stage 1 | $4.00B | $3.44B | $6.78B |
| Year 3 ✦ | Stage 1 | $4.40B | $3.51B | $10.29B |
| Year 4 ✦ | Stage 1 | $4.70B | $3.48B | $13.77B |
| Year 5 ✦ | Stage 1 | $5.00B | $3.43B | $17.21B |
| Year 6 | Stage 2 | $5.20B | $3.31B | $20.52B |
| Year 7 | Stage 2 | $5.41B | $3.20B | $23.72B |
| Year 8 | Stage 2 | $5.62B | $3.08B | $26.80B |
| Year 9 | Stage 2 | $5.85B | $2.98B | $29.78B |
| Year 10 | Stage 2 | $6.08B | $2.87B | $32.65B |
| Terminal | — | TV=$117.6B | PV(TV)=$55.5B (63% of EV) | EV=$88.2B |
| Intrinsic Value | — | — | EV $88.2B − Net Debt → Equity / Shares | $151 |
How the price per share is derived: Each year's projected free cash flow is discounted back at WACC (7.80%) to get its present value. After Year 10, FCF grows at the terminal rate (2.5%) in perpetuity — the Gordon Growth formula gives a terminal value of FCF11 / (WACC − gT) = $117.6B. That terminal value is discounted back 10 years to today's dollars (PV of TV = $55.5B). Enterprise Value = PV of FCFs ($32.6B) + PV of TV ($55.5B) = $88.2B. Subtracting net debt gives equity value of $81.5B, divided by shares outstanding = $151 per share.
✦ Year-by-year analyst consensus FCF estimates (Base scenario)
Bull Scenario
Stage 1: 9.0% | Stage 2: 6.0% | Terminal: 3.0%
| Period | Stage | FCFF | PV of FCFF | Cumulative EV |
|---|---|---|---|---|
| Year 1 ✦ | Stage 1 | $4.00B | $3.71B | $3.71B |
| Year 2 ✦ | Stage 1 | $4.60B | $3.96B | $7.67B |
| Year 3 ✦ | Stage 1 | $5.20B | $4.15B | $11.82B |
| Year 4 ✦ | Stage 1 | $5.80B | $4.29B | $16.11B |
| Year 5 ✦ | Stage 1 | $6.40B | $4.40B | $20.51B |
| Year 6 | Stage 2 | $6.78B | $4.32B | $24.83B |
| Year 7 | Stage 2 | $7.19B | $4.25B | $29.08B |
| Year 8 | Stage 2 | $7.62B | $4.18B | $33.26B |
| Year 9 | Stage 2 | $8.08B | $4.11B | $37.37B |
| Year 10 | Stage 2 | $8.56B | $4.04B | $41.42B |
| Terminal | — | TV=$183.8B | PV(TV)=$86.7B (68% of EV) | EV=$128.1B |
| Intrinsic Value | — | — | EV $128.1B − Net Debt → Equity / Shares | $225 |
How the price per share is derived: Each year's projected free cash flow is discounted back at WACC (7.80%) to get its present value. After Year 10, FCF grows at the terminal rate (3.0%) in perpetuity — the Gordon Growth formula gives a terminal value of FCF11 / (WACC − gT) = $183.8B. That terminal value is discounted back 10 years to today's dollars (PV of TV = $86.7B). Enterprise Value = PV of FCFs ($41.4B) + PV of TV ($86.7B) = $128.1B. Subtracting net debt gives equity value of $121.5B, divided by shares outstanding = $225 per share.
🔲 Sensitivity Table
| WACC \ gT | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.8% | $175 | $193 | $216 | $247 | $292 |
| 6.3% | $155 | $168 | $185 | $207 | $238 |
| 6.8% | $138 | $149 | $162 | $178 | $199 |
| 7.3% | $125 | $133 | $143 | $156 | $171 |
| 7.8% | $113 | $120 | $128 | $138 | $150 |
| 8.3% | $104 | $109 | $116 | $123 | $133 |
| 8.8% | $95 | $100 | $105 | $111 | $119 |
| 9.3% | $88 | $92 | $96 | $101 | $107 |
| 9.8% | $82 | $85 | $89 | $93 | $98 |
Green = >10% above current price. Red = >10% below. Gold = within ±10%.
📉 Long-Term Price Trend Channel
Log-linear trend fitted to full price history. ±1.5σ bands. Green shaded zone = bottom 25% of historical range — historically attractive entry.
🏦 Comparable Valuation
| Company | P/E (Fwd) | EV/EBITDA | P/FCF | Div Yield | Note |
|---|---|---|---|---|---|
| 3M (MMM) | 16.4x | 12.8x | ~54x* | 2.2% | FCF depressed; normalizing |
| Honeywell (HON) | 22.1x | 15.2x | 26.1x | 2.0% | Peer industrial conglomerate |
| Emerson Electric (EMR) | 24.8x | 17.0x | 25.6x | 1.8% | Automation focus |
| Illinois Tool Works (ITW) | 27.8x | 19.2x | 28.5x | 2.1% | Dividend King, high margins |
| Parker Hannifin (PH) | 24.5x | 16.5x | 22.9x | 1.1% | Industrial motion/control |
| MMM 5-yr avg | 19.0x | 14.5x | — | 3.5% | Historical reference |
💰 Dividend / Distribution Analysis
| Metric | Value |
|---|---|
| Annual DPS | $3.120 |
| Current Yield | 2.18% |
| Consecutive Growth Years | 0 |
| 1-yr DPS CAGR | +5.0% |
| 3-yr DPS CAGR | +-20.0% |
| 5-yr DPS CAGR | +-12.0% |
| 10-yr DPS CAGR | +1.0% |
| Payout Ratio (DPS/EPS) | 52.0% |
| FCF Payout Ratio | 119.0% ⚠️ |
| Sustainability Verdict | Watch |
MMM cut its dividend ~54% in 2024 following the Solventum spin-off. The new $3.12/share annualized payout is well-covered at 52% of FY2025 EPS and FCF is recovering ($1.4B in 2025 vs. $638M in 2024). PFAS liabilities remain a wild card for FCF trajectory through 2028. Verdict: Watch — payout is safe at current levels but PFAS settlement cash flows limit dividend growth to 4–6%/yr near-term.
🔮 Analyst Forecast Section
(a) EPS Consensus
| Year | Low / Actual | Avg | High | # Analysts | Type |
|---|---|---|---|---|---|
| 2021 | $10.12 | — | — | — | Actual |
| 2022 | $10.18 | — | — | — | Actual |
| 2023 | $-12.63 | — | — | — | Actual |
| 2024 | $7.55 | — | — | — | Actual |
| 2025 | $6.00 | — | — | — | Actual |
| 2026 | $8.38 | $8.73 | $9.20 | 21 | Estimate |
| 2027 | $8.84 | $9.49 | $10.22 | 19 | Estimate |
(b) Revenue Consensus
| Year | Low / Actual | Avg | High | # Analysts | Type |
|---|---|---|---|---|---|
| 2021 | $35.4B | — | — | — | Actual |
| 2022 | $26.2B | — | — | — | Actual |
| 2023 | $24.6B | — | — | — | Actual |
| 2024 | $24.6B | — | — | — | Actual |
| 2025 | $24.9B | — | — | — | Actual |
| 2026 | $24.4B | $25.4B | $27.0B | 21 | Estimate |
| 2027 | $25.0B | $26.2B | $27.6B | 19 | Estimate |
(c) Individual Analyst Price Targets
| Analyst | Firm | Rating | PT | Upside |
|---|---|---|---|---|
| Nicole Deblase | Deutsche Bank | Hold | $181 | +26.5% |
| Andrew Kaplowitz | Citigroup | Hold | $175 | +22.3% |
| Joe O'Dea | Wells Fargo | Buy | $175 | +22.3% |
| Chris Snyder | Morgan Stanley | Hold | $165 | +15.4% |
| Deane Dray | RBC Capital | Sell | $136 | -4.9% |
💡 Investment Thesis
- Post-restructuring earnings recovery: EPS expected to rebound ~45% to $8.73 in FY2026 as one-time charges roll off and operational efficiency improves; dividend growth should follow.
- Legal liability clarity: The $10.3B PFAS water utility settlement and $6.0B Combat Arms settlement remove the two largest overhang risks; remaining PFAS exposure is material but manageable vs. FCF.
- Leaner, focused business model: Post-Solventum spin, 3M is a pure-play industrial/consumer company with higher margin potential and cleaner capital allocation.
- Capital return commitment: Company reinstituted dividend growth in 2026 ($0.78/qtr vs. $0.73); buyback program restarted ($3.25B repurchased in FY2025).
- Valuation discount: At 16x forward earnings and 2.2% yield, MMM trades at a significant discount to its 5-year median P/E of 19x as legacy liabilities weigh on sentiment — creating a potential re-rating opportunity.
⚖️ DCF Verdict: Hold — 3M Company (MMM)
Current price: $143.04 | Analyst Avg PT: $174.25
$78
🔴 Bear
$151
📊 Base
$225
🚀 Bull
| Tier | Price | Action |
|---|---|---|
| Tier 1 — Starter | ≤$139 | Begin position |
| Tier 2 — Add | ≤$114 | Add on weakness |
| Tier 3 — Full | ≤$82 | Full allocation |
| Sell Alert | ≥$191 | Above fair value — consider trimming |
How tiers are set: Tier 1 = Base IV × 0.92 (8% discount to base case). Tier 2 = midpoint of Bear & Base IV (building on meaningful weakness). Tier 3 = Bear IV × 1.05 (just above worst-case — maximum margin of safety). Sell alert = Bull IV × 0.85 (15% discount to bull case — above fair value range).
Initiate at Accumulate with a Base DDM price target of ~$160–170. 3M has navigated its worst period and is entering an earnings recovery phase; the post-spin restructuring and legal settlements provide a cleaner setup for 2026–2028 growth.
Build a position in the $130–145 range where downside is limited by the 2.2% yield and legacy liability resolution; avoid a full position until PFAS liability trajectory is clearer. Becomes a Strong Buy below $120 if FCF recovers above $3B in 2026.
🔧 Model Notes & Calibration
| Assumption | Rationale / Notes |
|---|---|
| DPS Base | Using $3.12/share ($0.78/qtr × 4) — the post-spin reset level initiated in Q1 2026. FY2025 actual DPS was $2.92 reflecting the transition year. |
| Dividend Reset Context | MMM cut its dividend from ~$6.00 to ~$2.80 in 2024 following the Solventum spin-off. The new ~$3.12 annualized payout is appropriate for the standalone 3M. The 66-year Dividend King streak ended; MMM is now re-building its capital return track record. |
| Ke = 9.03% | CAPM: Rf=4.35% (10yr UST) + β=0.85 × ERP=5.5% = 9.03%. MMM is a mature industrial with below-market beta. |
| Sanity Check | Base DDM IV ~$155–170 vs. analyst consensus PT $174.25 — within ±20% threshold. ✅ |
| FCF Recovery Assumption | FY2024 FCF was depressed at $638M due to large PFAS settlement payments. FY2025 FCF recovered to $1.4B. Base case assumes FCF reaches $2.5–3.0B by FY2027 as settlement payments normalize. DDM model anchors to DPS growth, not FCF directly. |
| PFAS Liability | $10.3B PFAS water utility settlement being paid over 13 years (2023–2036) — ~$800M/yr headwind to FCF. This is a key reason DPS growth in Stage 1 is moderate (6%/yr base) despite strong EPS recovery. |
Bore Family Office • Analysis generated by Lurch • Not investment advice.